Objective To estimate the cost of scaling up childhood immunization services required to reach the WHO-UNICEF Global Immunization Vision and Strategy (GIVS) goal of reducing mortality due to vaccine-preventable diseases by two-thirds by 2015. Methods A model was developed to estimate the total cost of reaching GIVS goals by 2015 in 117 low-and lower-middleincome countries. Current spending was estimated by analysing data from country planning documents, and scale-up costs were estimated using a bottom-up, ingredients-based approach. Financial costs were estimated by country and year for reaching 90% coverage with all existing vaccines; introducing a discrete set of new vaccines (rotavirus, conjugate pneumococcal, conjugate meningococcal A and Japanese encephalitis); and conducting immunization campaigns to protect at-risk populations against polio, tetanus, measles, yellow fever and meningococcal meningitis.
Introduction
In 2005, the World Health Assembly approved, and the United Nations Children's Fund (UNICEF) Executive Board endorsed, the Global Immunization Vision and Strategy (GIVS).
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The primary objective of GIVS is to reduce vaccine-preventable disease mortality and morbidity by two-thirds by 2015 compared to 2000, a contribution towards achieving the Millennium Development Goals, especially Goal 4, which calls for a two-thirds reduction of under-5 mortality by 2015.
munization to other critical health interventions; and managing vaccination programmes and activities within the context of global interdependence. GIVS articulates more than 25 new ideas and innovative approaches, and it is anticipated that countries will adopt the strategies most suited to their needs.
GIVS was developed in the context of increasing resources for immunization; in 1999 a public-private partnership, The Global Alliance for Vaccines and Immunization (GAVI Alliance) was initiated to provide financial support for immunization in the world's poorest countries. [4] [5] [6] By the end of 2005, government and private sources had pledged a total of US$ 3.3 billion to the GAVI Alliance, enabling it to provide support to 73 of 75 eligible countries. Between 2000 and 2005, total GAVI Alliance disbursements were US$ 760.5 million.
7 GAVI Alliance's resource outlook over the next decade has improved with the launch of two innovative funding mechanisms: the International Finance Facility for Immunisation (IFFIm), 8 which could provide up to US$ 4 billion over the next 10 years, and the Pneumo Advance Market Commitment (AMC), 9 which will provide US$ 1.5 billion to support low-income countries for the purchase of new vaccines against Streptococcus pneumoniae, a leading cause of childhood meningitis and pneumonia mortality.
In 2005, WHO and UNICEF undertook, as a companion to the GIVS document, to estimate the costs to reach immunization goals; 10 this paper reports on the methods and results of that initial exercise.
Methods

Countries included
Estimates were done for all low-and lower-middle-income countries (as of 2003) 11 focusing on the subset of GAVI Alliance-eligible countries 12 (for 2005-2010 , countries with 2003 gross national income (GNI) per capita < US$ 1000), whose characteristics 11, 13, 34 are highlighted in Table 1 .
Cost components included
The costing has two main components: the first estimates current spending for immunization as of 2005 and how much will be needed to maintain the current immunization system. The second component estimates the incremental costs needed to scale up immunization coverage, including routine delivery and campaigns, and to introduce all available and safe vaccines according to WHO recommendations, including a finite set of new vaccines expected to become widely available (see Fig. 1 ).
For vaccine-specific costs, we define "traditional" vaccines as those in widespread use in the Expanded Programme on Immunization (EPI): Baccillus Calmette-Guérin (BCG), three doses each of diphtheria-tetanuspertussis (DTP) and oral polio vaccine (OPV); (we assume use of this ceases in 2010 following polio eradication), a single dose of measles vaccine (MCV1) for children under one year of age, and two doses of tetanus toxoid (TT2+) vaccine for pregnant women. "Underused" vaccines include a second dose of measles (MCV2); three doses of hepatitis B (HepB) and Haemophilus influenzae type b (Hib) vaccines; yellow fever (YF); and rubella. "New" vaccines include three doses of rotavirus and conjugate pneumococcal vaccines; and single doses of Japanese encephalitis (JE) and conjugate meningococcal A (MenA) vaccine, for populations at risk.
Deriving country-specific projections
Costs are projected using the following assumptions: (a) routine coverage of existing vaccines based on actual 2005 country-specific immunization schedules in use reaching 90% by 2015; (b) mortality reduction campaigns; and (c) introduction of underused and new vaccines as rapidly as feasible. We developed a Microsoft Excel-based framework to generate country-specific coverage estimates and projections, the WHO Immunization Coverage Estimates and Trajectories (WHO ICE-T) 14 (Annex 1, available at: http://www.who.int/ immunization_financing/analyses/ givs_costing_annex1.pdf ).
Four types of vaccination campaigns are included: for rapid mortality reduction (tetanus, measles); and in conjunction with the introduction of new or underused vaccines (yellow fever and meningococcal A). The schedule of campaigns occur in each country based on expected coverage levels, the joint UNICEF and WHO strategic plans for Measles Mortality Reduction 15 and Maternal and Neonatal Tetanus elimination, 16, 17 and the assumed year of introduction of new or underused vaccines. If the expected routine coverage levels are achieved by 2015, we assume no further immunization campaigns are needed, except occasionally in isolated areas with very low routine coverage.
We assume measles campaigns are needed until adequate routine two-dose coverage is reached; and schedule the occurrence of such campaigns every three years when routine first-dose coverage is under 75% and then every four years until first-dose routine coverage reaches 95% and routine second dose coverage reaches 90%. We assume that measles second-dose routine is introduced when a country reaches 80% routine firstdose coverage, and rubella vaccine is introduced after the first campaign following the introduction of routine second dose. Including a second dose of measles vaccine to the routine schedule adds a new visit to the schedule, another opportunity for children to contact the health-care system and receive other complementary interventions. Because of the complexity of adding a new visit to the schedule, we (conservatively) assume a five-year roll out to introduce a second dose.
For the introduction of underused (where not already used) and new vaccines, we assume phase-in over several years, based on grouping of countries by current immunization coverage and economic status (Annex 1, available at: http://www.who.int/immunization_ financing/analyses/givs_costing_annex1. pdf ). The dates of introduction of the pneumococcal, rotavirus, Hib, and HepB vaccines are country-specific, based on expert opinion, and it was assumed that in countries at risk, the YF vaccine would be introduced in 2006-2007, and 
Estimating country-specific costs
Estimating baseline costs (costing block A).
We developed an econometric model based on country-level data from the GAVI Alliance Financial Sustainability Planning (FSP) 18,19 process to estimate current investments in immunization and how much will be needed to maintain immunization systems at the status quo, assuming no change in vaccination schedules and constant immunization coverage levels.
These baseline data from 40 countries (country groupings and characteristics are listed in Table 1 ), use a common methodology comparable across the subset of countries and are relatively recent (2002) (2003) (2004) . However, they are biased towards low-income countries (82%) because of GAVI Allianceeligibility requirements and because the African Region is over-represented (57%).
All routine immunization-specific costs (see costing block C for a description of what is included in these costs), excluding spending on vaccines and campaigns, which we estimate separately in costing blocks B and D respectively, are included. 20 To these were added shared health systems costs (mainly personnel and transportation costs selection techniques of backward and forwards stepwise selection were used to find the optimal combinations of variables to include in the regression model. 25 We used nonparametric graphical modelling techniques 26, 27 to find the optimal transformations of both independent and dependent variables, and the "leaps and bounds" regression technique 28 to determine which effects should be included in the model built from the transformed variables. Of over 270 models considered, the final model which simultaneously yielded good explanatory power (R ² = 81%), had no violation of regression assumptions and had relative parsimony, and did not appear to systematically underestimate the total costs across the 40 data points used in estimating the model. Further details on this model can be found in Annex 2 (available at: http:// www.who.int/immunization_financing/ analyses/givs_costing_annex1.pdf ).
The fitted regression equation is used to estimate total non-vaccine costs (inflation adjusted) for the 72 poorest countries for the years 2000-2015. We applied the same model to estimate the costs in the 45 lower-middle-income countries (see Table   1 ), acknowledging the limitation that this is extrapolating outside the support of the fitted regression.
Uncertainty bounds are based on applying standard formulae 29 for predicting new observations from a fitted regression equation. The relative width of the uncertainty intervals for the baseline costing estimates was applied to estimates from other cost categories (B, C and D) to obtain overall uncertainty bounds.
Vaccine costs (costing block B)
We estimate the costs of traditional, un- 30 For new vaccines, prices are based on assumptions derived from available data and expert opinion, together with an assumption that prices will drop towards a "mature" price as demand rises. Vaccines are estimated as "bundled" costs, including safe injection supplies (syringes and safety boxes), and adjusted for wastage (based on vial sizes) and buffer stocks needed. Shipping and freight are also included as a percentage of the price per dose. Table 2 gives the assumed prices and assumptions used for wastage and freight charges applied to all countries. Costs for disposable items (e.g. syringes, safety boxes) are based on 2005 international prices and adjusted for inflation (3%) assuming wastage of 10% of the autodisposable syringes (US$ 0.074), reconstitution syringes (US$ 0.03) and safety boxes (100-syringe capacity, US$ 0.59).
The number of doses is based on the appropriate target population (births, surviving infants, women of childbearing age or as specified for a campaign) combined with expected coverage levels.
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Systems costs (costing block C) To estimate the costs of scaling-up coverage, we use country-specific variables to define likely production function rules for each component. The main assumptions and variables used for each component (both capital and recurrent costs) include a country classification used by the McKinsey 31 consulting firm in a report to the GAVI Alliance on barriers to immunization systems performance, the Commission on Macroeconomics in Health infrastructure index, 32 a transportation index based on types of available transport and communication, 33 district-level vaccine coverage and country-reported immunization-specific indicators. 34 The McKinsey classification groups countries into three types: TU or "turn around" countries, low performers where major system strengthening is required; SI, "strategic intervention" countries, middle performers in need of targeted interventions; and SA, "stand alone" countries, higher performers with good infrastructure. The classification is based on an assessment of political and financial commitment, physical infrastructure and equipment availability, monitoring and information systems, human resource availability and social mobilization strategies.
31 Table 3 presents a summary of these assumptions. For example, the percentage of districts with less than 50% DTP3 vaccine coverage is used as an indicator as to whether additional supervisory visits at the district level are required. Media and information, education and communication costs are based on whether the country has reported an existing budget for social mobilization (and, hence, these costs were included in the baseline systems costs, rather than being new costs). Transportation costs related to the cold chain are linked to estimates of the average distance between facilities at the national, provincial, district and health service delivery levels, with the transport quartile 33 determining the type of vehicle to be used and the average distance that can be travelled daily.
The analysis builds on a large database of parameters developed for the WHO-CHOICE 35 project, e.g. countryspecific prices for factor inputs such as stationery, fuel and other macro-and microeconomic parameters needed. Prices for immunization-specific items are obtained from Product Information Sheets.
36 Additional quantities are determined for items such as outreach personnel based on analysis of country financial sustainability planning documents.
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Campaign costs (costing block D) Delivery costs per person vaccinated, exclusive of cost of vaccines and vaccine supplies, in the different types of campaigns are based on data collected from several different country-level costing studies [37] [38] [39] [40] [41] [42] as well as those reported in the FSPs. 19 The unit costs per person 
2005
Block A: maintenance of current routine system (baseline cost) Current levels of investment in immunization were estimated using available data from 40 Financial Sustainability Plans (Block A1), and extrapolated for the period 2006-2015 by accounting for the impact of inflation and population increases (Block A3). They assume no change in vaccination schedules and no improvement in immunization coverage levels (Block A2). This does not include campaigns or vaccine costs.
Block B: vaccine costs
Vaccine costs were estimated by using coverage targets, population projections and applying the most recent available data on unit prices of different vaccine presentations. The estimates account for wastage rates and the need for buffer stock. The cost of safe injection equipment is bundled in the vaccine cost estimates. The element "below the line" represents the vaccine costs to continue immunization at 2005 levels, and "above the line" is the vaccine portion of scaling-up.
Block C: scaling-up of routine system
This is estimated using an ingredients-based approach. See Table 3 .
Block D: campaigns A schedule of needed campaigns was generated based on a combination of the projections of vaccine coverage and the required epidemiological coverage required to rapidly reduce the burden of disease. Campaign costs include both operational costs and vaccine costs.
targeted include training, cold chain equipment, social mobilization, waste management, salaries and per diem and transport costs.
Where a cost per person targeted, by campaign, is available for a country, we used that estimate; where it was unavailable, we estimated the costs by using averages across WHO subregions and regions, or by extrapolating the ratio between costs of other types of campaigns in another country and applying that to a single campaign cost estimate from the country. Measles catch-up (nine months to 14 years) and follow-up campaigns (nine months to four years) were estimated to cost between US$ 0.19-1.68 per person targeted. Campaigns associated with the introduction of yellow fever (nine months and up) and meningococcal vaccines (nine months to 29 years) ranged between US$ 0.17-1.53 per person targeted; and campaigns to reduce the burden of 
Findings
The total cost for immunization from 2006 to 2015, including the costs to maintain the existing immunization system, is estimated to be US$ 35.5 billion in the 72 GAVI Alliance-eligible countries (range: US$ 13-40 billion), of which 54% maintains current immunization efforts and the remaining 46% is for scaling-up (5% campaigns, 16% systems, 25% vaccines). This shows a considerable shift in the distribution of spending from systems to vaccines as more expensive vaccines are introduced: of the costs to maintain current routine immunization, 25% are for vaccines; in scaling up, 60% of the costs are for vaccines.
Applying the same methods (despite the potential limitations) to the remaining 45 lower-middle-income countries, we estimate an overall cost of US$ 76.1 billion (range: US$ 23-110 billion). Among the 45 lower-middleincome countries that are not GAVI Alliance-eligible, where baseline systems costs are estimated to be higher, 71% of the projected costs for 2006-2015 are for maintaining the current programmes, of which 13% goes towards vaccines; of the scaling-up costs, 69% will be for vaccines (Table 4) .
In GAVI Alliance-eligible countries, on average US$ 0.54 per capita (range: US$ 0.21-3.11 across countries), or US$ 24 (range: US$ 7-105) per child born, needs to be spent to maintain current immunization levels, varying with population size, DTP3 coverage and economic status. This needs to be nearly doubled to achieve the GIVS goals, resulting in a cost per capita of more cold-chain training and supervision investment compared (34% and 22%, respectively, of systems costs) to the late introducers of new vaccines, whose current immunization systems are not as strong (18% and 4%, respectively) and who need to make more substantial investments in core areas such as personnel and outreach (2% and 5% for high performers/early introducers; 21% and 23% for low performers/late introducers). In addition, the average incremental systems costs of scaling-up per child is more in the latter group (US$ 9) than the former (US$ 8), while the average incremental vaccine costs are lower (US$ 13) for late introducers than for early introducers (US$ 23). Our findings that US$ 16.2 billion is required to scale up immunization in the 72 poorest countries over the next 10 years are sensitive to underlying assumptions. As an example, we have assumed that the cold chain volume of a rotavirus vaccine will be 11.5 ml per dose, but the currently available presentation is nearly 112 ml per dose. If the larger vial size had been used in the costing, then an additional US $1.9 billion would be required, doubling the costs of scaling-up the cold chain, and increasing associated vehicle and transportation costs by 60%.
For the subset of GAVI Allianceeligible countries, Table 5 
Immunization coverage surveys Every 3 years
Development of strategies
If not already being done, costs for consultants and workshops to develop: -a 3-5 year strategic plan every 4 years -annual work plan for immunization services -plan for measles control every 4 years -plan for safe injection every 4 years -annual district microplans (for districts which do not already have one). Laboratory Capital cost to equip a bacteriological lab (for meningococcal, pneumococcal and Hib): 2 years prior to introduction of vaccine. Training and annual lab supplies. Capital cost to equip a lab for ELISA-based testing: 2 years prior to introduction of rubella, rotavirus, yellow fever, HepB, JE. Training and lab supplies.
Service delivery
Per diem for outreach, additional personnel (salaries)
All countries:
The annual number of outreach visits estimated by calculating 2005 capacity to deliver immunization visits, and assuming that 50% of the additional contacts will be delivered through outreach services, and the distribution of additional contacts across urban and rural areas.
TU and SI countries:
Annual estimates of the additional personnel at the district and health facility levels are estimated based on a regression model fit to FSP data, 19 using as covariates the number of nurses, DTP3 coverage changes, birth cohort size, population density, and urban/rural population distribution. The average salary of immunization staff at these levels is taken from the FSP 19 data where available, and from a regression model using FSP data to predict salaries from the size of the birth cohort, the proportion of the population living in urban areas, economic status, and government health expenditures where not available.
DTP3, Diphtheria-tetanus-pertussis, third dose; ELISA, enzyme-linked immunosorbent assay; FSP, Financial Sustainability Planning; HepB, hepatitis B; Hib, Haemophilus influenzae type b; JE, Japanese encephalitis; SOPs, standard operating procedures; UNICEF, United Nations Children's Fund.
( to achieve the GIVS. We assume an optimistic funding scenario based on available data 18, 19, [45] [46] [47] from national programmes, the GAVI Secretariat and the WHO Polio Team, and the funding gaps are shown in Table 5 .
For the 72 GAVI Alliance-eligible countries, about US$ 25 billion is estimated to be available for the 2006-2015 period, of which 16% is projected to come from national governments, 15% from the GAVI Alliance and 40% from external donors. Between 30% and 40% of need is unmet, an annual shortfall of more than US$ 1 billion.
The main unfunded area during the 2006-2015 period is vaccines. However, this becomes the case only when new vaccines become available in the longer term. In the medium term, the main unfunded elements will be for reaching more children, through strengthening systems and campaigns (Table 5) . Regionally, the largest funding gaps in absolute terms are in the South-East Asia and African Regions; by percentage, the largest gap is in the Eastern Mediterranean Region.
Discussion
Putting a cost estimate to an immunization vision, 2006-2015 is no doubt subject to uncertainty around the data and methods used, individual strategies chosen by each country to reach its visions, price uncertainties around vaccines and other inputs to national immunization programmes, and the availability of funds to finance continuous expansions and improvements of immunization. The uncertainty bounds around the cost estimates reflect these limitations. These costing figures should be taken as indicative approximations of what it may take to scale up immunization to reach GIVS goals over the next decade. The estimates for lower-middle-income countries have additional limitations due to much of the input data for predicting baseline costs, and price data for vaccines, being specific to poorer countries.
A further limitation of this analysis is that only a finite set of potential immunization interventions is included. The newly licensed human papillomavirus vaccine is not included, nor are vaccines against seasonal influenza, nor are global public goods, including research and development, global capacity to assist countries in crisis situations with stockpiles of vaccines (e.g. for cholera). All of these are possible strategies identified in the GIVS 2 and many of them will be pursued. There is a need to periodically update this costing exercise to reflect the strategies being pursued at the country level, and our improved understanding of the dynamics of immunization costing and financing. Nonetheless, the present analysis is based on realistic and rigorous assumptions, the best available data (as of 2005), and fills an important gap in knowledge.
Recognizing these limitations, we estimate that reaching immunization goals is achievable at a cost of US$ 35 billion during 2006-2015. By 2015, more than 70 million children in the world's 72 poorest countries can be protected annually against 14 major childhood diseases if an additional US$ 1 billion per year can be invested towards immunization. 10 This equates
Research
Costs of the WHO-UNICEF immunization strategy Lara J Wolfson et al. to an additional US$ 0.5 per capita per year above current levels (< US$ 1 per capita) of investment in immunization. At such modest costs and high benefits, immunization continues to be one of the best values for public health investment today. 44 Not only do immunizations save lives, but in impoverished countries they boost economies, potentially yielding a rate of return of up to 18%. 48 In addition, immunization can serve as a platform to strengthen health systems and deliver other life-saving interventions such as those against malnutrition, malaria and intestinal worms.
Despite being a good buy for the health sector, financing for immunization remains a significant challenge. A funding gap of between US$ 11 billion and US$ 15 billion is estimated to remain if the goal of saving 10 million more lives is to be achieved by 2015. This financing challenge exists despite the favourable context of significant additional new resources for immunization that are available through the GAVI Alliance, IFFIm, 8 the AMC 9 and other global efforts. There are growing concerns about the financial sustainability of future immunization efforts, and for many of the poorest countries, shared financial responsibility between national governments and international donors will be required. The cMYP process is a first step in translating the global into the local: a national immunization plan to implement appropriate strategies at country level. With the implementation of these plans, countries are paving the way towards sustainability of their current programmes and preparing themselves for the later generations of vaccines and technologies where financing requirements will grow.
The real challenge will hinge on how national governments, WHO, UNICEF and the international community at large, manage their roles and responsibilities in reaching and financing the goals of the GIVS until 2015. ■ 
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Résumé
Estimation des coûts pour réaliser l'objectif de l'initiative OMS-UNICEF « La Vaccination dans le monde : vision et stratégie » pour la période [2006] [2007] [2008] [2009] [2010] [2011] [2012] [2013] [2014] [2015] Objectif Estimer le coût du développement à plus grande échelle des services de vaccination infantile nécessaires à la réalisation de l'objectif de l'initiative OMS-UNICEF « La vaccination dans le monde : vision et stratégie (GIVS) », consistant à réduire des deux-tiers d'ici 2015 la mortalité due aux maladies évitables par la vaccination. Méthodes Un modèle a été élaboré pour estimer le coût total de la réalisation de l'objectif de cette initiative d'ici 2015 dans 117 pays à revenu faible ou faible à moyen. Les dépenses actuelles ont été estimées par une analyse des documents de planification nationale et les coûts du passage à l'échelle supérieure en utilisant une démarche partant de la base et des intrants. Les coûts financiers pour atteindre une couverture vaccinale de 90 % ont été estimés par pays et par année pour tous les vaccins existants, dans le cas où l'on introduirait une série discrète de nouveaux vaccins (vaccins antirotavirus, antipneumococcique conjugué, contre le méningocoque de type A et contre l'encéphalite japonaise) et dans celui où l'on mènerait des campagnes de vaccination pour protéger les populations à haut risque contre la polio, le tétanos, la rougeole, la fièvre jaune et la méningite à méningocoque. Résultats Les 72 pays les plus pauvres du monde ont consacré US$ 2,5 milliards (plage de variation : US$ 1,8-4,2) à la vaccination en 2005, soit une augmentation de US$ 1,1 milliard Objetivo Estimar el costo de extender masivamente los servicios de inmunización infantil requeridos para alcanzar la meta de la Visión y Estrategia Mundial de Inmunización (GIVS) OMS-UNICEF de reducir la mortalidad por enfermedades prevenibles mediante vacunación en dos tercios para 2015. Métodos Se elaboró un modelo para estimar el costo total del logro de las metas de GIVS para 2015 en 117 países de ingresos bajos o medios bajos. El gasto actual se estimó a partir de datos extraídos de los documentos de planificación de los países, y los costos de la extensión masiva se estimaron mediante un método ascendente basado en componentes. Se calcularon los costos financieros requeridos por país y año para alcanzar una cobertura del 90% con todas las vacunas existentes; introducir un conjunto de vacunas nuevas (contra rotavirus, antineumocócica conjugada, conjugada contra el meningococo A y contra la encefalitis japonesa); y realizar campañas de inmunización para proteger a las poblaciones de riesgo contra la poliomielitis, el tétanos, el sarampión, la fiebre amarilla y la meningitis meningocócica. Resultados Los 72 países más pobres del mundo invirtieron US$ 2500 millones (intervalo: US$ 1800 -4200 millones) en actividades de inmunización en 2005, lo que supone un aumento respecto a los US$ 1100 millones (intervalo: US$ 900 -1600 millones) de 2000. Para 2015, los costos anuales de la inmunización aumentarán por término medio a unos US$ 4000 millones (intervalo: US$ 2900 -6700 millones). Los costos totales de la inmunización para 2006-2015 se estiman en US$ 35 000 millones (intervalo: US$ 13 000 -40 000 millones); de esa cantidad, US$ 16 200 millones son costos adicionales, de los que US$ 5600 millones corresponden a la expansión del sistema References y US$ 8700 millones a las vacunas; se necesitan US$ 19 300 millones para mantener los programas de inmunizacion a los niveles de 2005.
En el conjunto de los 117 países de ingresos bajos y medios bajos, se estima que los costos totales para 2006 -2015 ascenderán a US$ 76 000 millones (intervalo: US$ 23 000 -110 000 millones): US$ 49 000 millones para mantener los sistemas actuales y US$ 27 000 millones para expandirlos.
Conclusión Considerando los 72 países más pobres, se necesitan aún US$ 11 000 -15 000 millones (30% -40% de los recursos globales necesarios) para poder alcanzar las metas de la GIVS. Los métodos desarrollados en este artículo arrojan estimaciones aproximadas que presentan limitaciones, pero proporcionan una hoja de ruta para financiar los déficits que hay que cubrir a fin de expandir la inmunización para 2015. 
‫ملخص‬
